A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease.

Antiviral Research
V L FowlerP V Barnett

Abstract

Protection against foot-and-mouth disease (FMD) using DNA technology has been documented for sheep and pigs but not for the highly susceptible species of cattle. Twenty-five Holstein Friesian cross-bred cattle were vaccinated twice, 21 days apart, with a DNA vaccine containing the capsid coding region (P1) along with the non-structural proteins 2A, 3C and 3D (pcDNA3.1/P1-2A3C3D) of O(1) Kaufbeuren alone or coated onto PLG (d,l-lactide-co-glycolide) microparticles. In some pcDNA3.1/P1-2A3C3D was also combined with an adjuvant plasmid expressing bovine granulocyte macrophage colony stimulating factor (GM-CSF). DNA vaccinations were administered intramuscularly with, or without, the use of electroporation and at 42 days post primary vaccination cattle received a protein boost of 146S FMD virus (FMDV) antigen and non-structural protein 3D. For comparison, four cattle were vaccinated with a conventional FMD vaccine and two more included as unvaccinated controls. Apart from those immunised with PLG microparticles all cattle were challenged with 10(5) TCID(50) cattle adapted O(1) Lausanne FMDV virus at day 93 post primary vaccination. All DNA vaccinated cattle regardless of regime developed good humoral and cell mediated responses pri...Continue Reading

References

Jun 3, 2000·Annual Review of Immunology·S GurunathanR A Seder
Mar 17, 2001·Intervirology·K Cichutek
Mar 21, 2001·Vaccine·S van Drunen Littel-van den HurkL A Babiuk
Jan 16, 2003·Virus Research·T R Doel
Jul 16, 2003·Journal of Comparative Pathology·S AlexandersenA J M Garland
Feb 15, 2005·Journal of the American Veterinary Medical Association·Ann H DavidsonM D Salman
Apr 3, 2007·Journal of Virological Methods·Andrew E ShawDonald P King
Aug 19, 2008·Vaccine·S van Drunen Littel-van den HurkJ V van den Hurk
Oct 22, 2011·Veterinary Research·Miriam A WindsorBryan Charleston

❮ Previous
Next ❯

Citations

Dec 12, 2012·Clinical and Vaccine Immunology : CVI·Sylvia van Drunen Littel-van den HurkDrew Hannaman
Sep 27, 2013·Expert Review of Vaccines·Luigi AurisicchioGennaro Ciliberto
Nov 5, 2016·The Veterinary Journal·J ImpellizeriD M Soden
Jan 19, 2019·Critical Reviews in Biotechnology·Ana Clara MignaquiAndrés Wigdorovitz
Sep 24, 2016·Oncotarget·Viswa Teja Colluru, Douglas G McNeel
Mar 20, 2019·Archives of Virology·Mohamed KamelHugo Castañeda Vazquez
Mar 5, 2019·Current Medicinal Chemistry·Shuang YuKai Zhao
Dec 29, 2020·Frontiers in Bioengineering and Biotechnology·Teresia W MainaJodi L McGill
Dec 8, 2020·Frontiers in Bioengineering and Biotechnology·Sankar Renu, Gourapura J Renukaradhya
Mar 16, 2018·Current Opinion in Virology·Teresa de Los SantosLuis L Rodriguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.